%0 Journal Article
%T A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease.
%A Gonzalez-Ortiz F
%A Ferreira PCL
%A González-Escalante A
%A Montoliu-Gaya L
%A Ortiz-Romero P
%A Kac PR
%A Turton M
%A Kvartsberg H
%A Ashton NJ
%A Zetterberg H
%A Harrison P
%A Bellaver B
%A Povala G
%A Villemagne VL
%A Pascoal TA
%A Ganguli M
%A Cohen AD
%A Minguillon C
%A Contador J
%A Suárez-Calvet M
%A Karikari TK
%A Blennow K
%J Alzheimers Dement
%V 20
%N 2
%D 2024 02 17
%M 37975513
%F 16.655
%R 10.1002/alz.13525
%X Detection of Alzheimer's disease (AD) pathophysiology among individuals with mild cognitive changes and those experiencing subjective cognitive decline (SCD) remains challenging. Plasma phosphorylated tau 217 (p-tau217) is one of the most promising of the emerging biomarkers for AD. However, accessible methods are limited.<BR>We employed a novel p-tau217 immunoassay (University of Gothenburg [UGOT] p-tau217) in four independent cohorts (n = 308) including a cerebrospinal fluid (CSF) biomarker-classified cohort (Discovery), two cohorts consisting mostly of cognitively unimpaired (CU) and mild cognitively impaired (MCI) participants (MYHAT and Pittsburgh), and a population-based cohort of individuals with SCD (Barcelonaβeta Brain Research Center's Alzheimer's At-Risk Cohort [β-AARC]).<BR>UGOT p-tau217 showed high accuracy (area under the curve [AUC] = 0.80-0.91) identifying amyloid beta (Aβ) pathology, determined either by Aβ positron emission tomography or CSF Aβ42/40 ratio. In individuals experiencing SCD, UGOT p-tau217 showed high accuracy identifying those with a positive CSF Aβ42/40 ratio (AUC = 0.91).<BR>UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum.